Age-specific challenges add to the complexity of providing health care in pediatric and young adult transplant recipients. Project 6 is the first comprehensive, multi-organ transplant study to identify age-related biologic and health care systems determinants of variability in immunosuppression control in children and youth. Results will inform personalized age-appropriate strategies to improve immunosuppression control and reduce the unacceptably high rates of graft failure, GVHD and viral complications in this vulnerable population. 

What is the Canadian National Transplant Research Program (CNTRP)?

 

The CNTRP was created to bring together researchers from many transplant disciplines across Canada. Designed to transform transplant research in Canada, the CNTRP aims to increase the number of transplants and improve the survival of recipients on a national scale.
 
The CNTRP is funded by the Canadian Institutes for Health Research (CIHR) Institute of Infection and Immunity and other funding agencies. This network is composed of 105 investigators at 17 centres and universities across 9 provinces.  This program supports 6 projects and 3 cores. The POSITIVE study is a project focused primarily on improving outcomes in children after transplant.

 

Purpose of the POSITIVE Study 

 

Adequate control of immunosuppression is essential to prevent graft failure after   transplantation and to avoid life-threatening viral and malignant complications.  Children undergo periods of rapid change from birth to young adulthood as their bodies change with growth and maturation; this makes achieving optimal immunosuppression in children difficult.
 
The POSITIVE study aims to tailor post- transplant management to the unique needs of growing children and young adults with the goal of prolonging graft survival, delaying re-transplantation and ultimately improving the long-term quality of life of patients post transplant.
 
We will study ways to adjust the type and dose of medicines after transplant uniquely for each child, ways to reduce the risk of developing viral and malignant complications, and ways to improve adherence with medicines after transplant.

Collaborators
  • Philip Acott, IWK Health Centre

  • Fernando Alvarez, Université de Montréal

  • Yaron Avitzur, The Hospital for Sick Children

  • Mona Beaunoyer, Université de Montréal

  • Lut Berben, Basel University, Switzerland

  • Jennifer Conway, University of Alberta

  • Sabina De Geest, Basel University, Switzerland

  • Frank Dicke, University of Calgary

  • Janusz Feber, Children's Hospital of Eastern

  • Hartmut Grasemann, The Hospital for Sick Children

  • Norine Heywood , McGill University

  • Binita Kamath, The Hospital for Sick Children

  • Stephanie Laer, University of Dusseldorf

  • Valerie Langlois, The Hospital for Sick Children

  • Anne-Laure Lapeyraque, Université de Montréal

  • Steve Martin, University of Calgary

  • Catherine Morgan, Stollery Children’s Hospital

  • Vicky Ng, The Hospital for Sick Children

  • Hema Patel, McGill University

  • Marie-Josee Raboisson, Université de Montréal

  • Kirk Schultz, University of British Columbia

  • Jan Storek, University of Calgary

  • Jean Tchervenkov, McGill University

  • Yves Théorêt, Université de Montréal

  • Jason Yap, Stollery Children’s Hospital

POSITIVE Study Team

 

Project Leads
  • Dr. Seema Mital, The Hospital for Sick Children

  • Dr. Upton Allen, The Hospital for Sick Children

  • Dr. Bethany Foster, McGill University 

 

Researchers
  • Lorraine Bell, McGill University 

  • Patricia Birk, University of Winnipeg 

  • Janice Bissonnette, University of Ottawa 

  • Tom Blydt-Hansen, University of Winnipeg 

  • Heloise Cardinal, Université de Montréal 

  • Lee Dupuis, The Hospital for Sick Children 

  • David Grant, The Hospital for Sick Children 

  • Lorraine Hamiwka, University of Calgary 

  • Jennifer Harrison, Toronto General Hospital 

  • Diane Hebert, The Hospital for Sick Children

  • Olwyn Johnston, University of British Columbia 

  • Catherine Litalien, Université de Montréal 

  • Istvan Mucsi, McGill University 

  • Rulan Parekh, The Hospital for Sick Children 

  • Veronique Phan, Université de Montréal 

  • Lisa Robinson, The Hospital for Sick Children 

  • Susan Samuel, University of Calgary 

  • Tal Schechter-Finkelstein, The Hospital for Sick Children 

  • Simon Urschel, University of Alberta

Understanding, predicting and preventing early graft rejection and GVHD:

  • Black Facebook Icon
  • Black Twitter Icon
  • Black YouTube Icon

© 2014 by the CDTRP

All rights reserved